Biomarker profiling for risk of future heart failure (HFpEF) development

Journal of Translational Medicine

James O’Reilly¹  Ken McDonald²  Joe Gallagher²  Mark Ledwidge²  Isaac Tea³  Shuaiwei Zhou⁴  Eoin O’Connell⁴  Mark Wilkinson⁴  Stephanie James⁴  Adam Russell-Hallinan⁵  Chris J. Watson⁶ 

[1] Conway Institute, University College Dublin, Dublin 4, Ireland;Conway Institute, University College Dublin, Dublin 4, Ireland;St. Vincent’s University Hospital Healthcare Group, Dublin 4, Ireland;Internal Medicine, Lankenau Medical Center, 19096, Wynnewood, PA, USA;St. Vincent’s University Hospital Healthcare Group, Dublin 4, Ireland;Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, BT9 7BL, Belfast, Northern Ireland;Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, BT9 7BL, Belfast, Northern Ireland;Conway Institute, University College Dublin, Dublin 4, Ireland;St. Vincent’s University Hospital Healthcare Group, Dublin 4, Ireland;

关键词: Heart failure;    HFpEF;    Risk factors;    Biomarkers;   

DOI  :  10.1186/s12967-021-02735-3

来源: Springer

【 摘 要 】

BackgroundThe purpose of this study was to investigate the utility of BNP, hsTroponin-I, interleukin-6, sST2, and galectin-3 in predicting the future development of new onset heart failure with preserved ejection fraction (HFpEF) in asymptomatic patients at-risk for HF.MethodsThis is a retrospective analysis of the longitudinal STOP-HF study of thirty patients who developed HFpEF matched to a cohort that did not develop HFpEF (n = 60) over a similar time period. Biomarker candidates were quantified at two time points prior to initial HFpEF diagnosis.ResultsHsTroponin-I and BNP at baseline and follow-up were statistically significant predictors of future new onset HFpEF, as was galectin-3 at follow-up and concentration change over time. Interleukin-6 and sST2 were not predictive of future development of new onset HFpEF in this study. Unadjusted biomarker combinations of hsTroponin-I, BNP, and galectin-3 could significantly predict future HFpEF using both baseline (AUC 0.82 [0.73,0.92]) and follow-up data (AUC 0.86 [0.79,0.94]). A relative-risk matrix was developed to categorize the relative-risk of new onset of HFpEF based on biomarker threshold levels.ConclusionWe provided evidence for the utility of BNP, hsTroponin-I, and Galectin-3 in the prediction of future HFpEF in asymptomatic event-free populations with cardiovascular disease risk factors.

【 授权许可】

CC BY